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ase.wd in 50 ptknk with &al fhilkttw m OWkr. 
Treatment WPF cmddued saccsdnt it s+nm rbyibn oc- 
NRvd within 1 a. converskm to tinns *a9 adlkvd to 1t 
(55%) of 20 p,,tlnts with atrkl Abrltktkn treakd with 
pmpafenwe and to IS (90%) of 20 wltb ati librlwka 
treati wttb tkmbddt (p C 0.02). If atrkl fibrlllatkm ~LS 
pEs?nt 524 b, novDti to slmu *&m w$3 xbkved lo 
8 (57%) d 14 patlm(s ia the pmtmfcnw grwa al6 13 
(93%) cft4lntbellssinkkgn~~p (p < 0.03). AtaW&atter 
wps mmertcd tn two (40%) of kc ptkids treated wltb 
;imme and io one (20%) of tlve with ikalnlde lp = 
Mean time to movctsloo was 16 * 10 min b the 
pwpafenooe &mop versus 18 f 13 mln lo the llwlnide 
Prcpafenone hydrochloride has been classified as a class IC 
antiarrhyihmic agent with weak beta-adrenoceptor antago- 
nist activity. It primarily slows intraatrial and atrioventricu- 
lar (AV) node conduction (I). Clinically, no substantial 
increase in atrial refractoriness has been observed. I’m- 
p&none is useful for the management of padats with 
various forms of ventricular and supravenuiculv tachycw 
dias (l-9). Recent studies have demonstrated that intmw 
nous pmpafenone is potentially effective in terminating 
paroxysmal atrial librillation and in controlling ventricular 
response during atrial fibriUation with only minor side effects 
(10-12). However, the drug seems less effective in patients 
with atrial flutter (12). 
Fkoainide acetate is a class IC ontiarrbytb~.tic agent 
currently used in both ventricular and supraventricular ar- 
rbyihmias (13-25). It slows intracardiac canductmn and 
prolongs the rcfractoty period to a lener extent (P-17). We 
(24) have shown in a previous study that Recainide is very 
effective for immediate conversion of recent onset atrial 
fibrillation but its use is complicated by drug-related side 
e5ects and it seems to be ine&ctive for atrial Rultcr. 
The value of prop&woe as an antianbythmlc agent for 
conversicn of paroxysmal atrial fibrillation or flutter. as 
compared with tht-t of more frequently used drugs such as 
quinidine or flectinide, is oat well established. This cornpar- 
ative study was undertaken to determine the efficacy and 
safety of intraveoous propafeoone versus Recairdde for 
conversion of atrial tibrillation or flutter to sinus rhythm 
within : h. The relation between plasma kxls and eR~ctive- 
ness of both drugs was alw studied 
Study palien’s. Fifty consecutive palmls (34 men and 
16 womeni Z’7 to 78 rr ars old (mean 59 e 14) were selected 
for this s:udy. which was approved by the tnrlttutional 
review board. They wre entered into the study if there was 
atrill fibrillation or Runer laslmg ~6 v-?hs with a wrric- 
u!ar tale SKY bealsimin ar rcsl and n‘ szgns of heart !rilure 
Exclusian criteria were any previous!y documented or EUI- 
pected conduction disturbances of more than first degree AV 
block, concomitant therapy with class I antiarrhylhmic 
drugs, W&T-Parkinson-White syndrome. sick sinus syn- 
drome, acute myocardial infarction. hyperlhyroidrsm. car- 
diac surgery within 2 weeks before the start of the study. left 
atria! enlargement with atria1 fibrillation or flutter lastmf >? 
days without appropriate anticoagulation therapy. eleclru- 
lyre imbalance and body weight ,100 kg. 
Tretdmml pmlocd. A complete medtcal history. physi- 
cal examination, routine biochemical laboratory testing. 
chest X-ray film and a I2 lead electrocardiogram (ECGI were 
performed before admi&ralion of the drug. If the chest 
X-rw film showed siens of cardiac enlarwwnl. additional 
two-dirneusional eeh&ardiography was ;crformed before 
the start of treatment. The patients were observed for at 
least 30 min before adminiskdion uf either drug to allow 
their condition to stabilize. In x:en patients with atria1 
fihriUaiion who had qualified ior enrulimant spontaneous 
catversion lo sinus rhythm occurred before the start of the 
study. A&r informed convcot was obtained, the patisots 
UIR randomly assigned to treatment with either intravenaus 
propafenone or Recainide. During I h after administration of 
either drug, the patient’s rhythm was continuously mcli- 
tored. Treatment was considered successful ifconversion lo 
sinus rhythm occurred within 60 min after start of the 
infusion. If sinus rhythm was not restored, patients were 
treated with direct current cardioversion or with other 
anliarrhylhmic drugs. or both. 
A I2 lead ECG war recorded as soon as conversion to 
sinus rhythm occurred and al 60 min after start of Ihe 
infusion. The ECC intervals were assessed just before start 
of tha infusion and at 60 min. The RR interval, QRS interval, 
QT interval, corrected QT interval (QTc = QTI- and 
aVial flutter wave interval, where appropriate, were CPICU- 
laled from a mean of five consecutive beats. 
Drug admi1Glratio0 and plasma ssmplii. Propafenone 
hydrochloride and Recainide acetate. both at .Q dose of 
2 @kg body weight, were administered intravent~usly in
10 min. Fiasms samples were collected at 20 and 60 mitt and 
also ~1 the time ofconversmn to sinus rhythm. Delemdna- 
lion of plasma lsvels of both drugr was done by means of 
high pressure liquid chromatography. 
labb 1. Chnical Baneiinr Characteristics of 50 Ftudv ?alien!s” 
Stalistics. Wean values + SD were given Ccr continuous 
variables and were analyzed by rnean~ of Student’s I test for 
unpatred or paired variables where appropriate. Fisher’s 
exact lest was used to compare discontinuous variables. 
Results 
Patient characteristics (Table 1). The clinical characteris- 
tics wre fully comparable in both groups. Forty patients 
wtth paroxysmal alrial librilla!ion and 10 with paroxysmal 
atria1 Rurler were entered into the study. Recent ooset 
(~24 h) atrial fibrillation was present in 28 (7%) and atria! 
flutter in 3 (3o%I patients. Twelve patients (3G%) bad long- 
standing 024 h) atria1 fibrillation and 7 (70%) had long_ 
standing atrial flutter. Sixteen patients had previously docu- 
mented episodes of paroxysmal alrird fthrillalion or flutter. 
Cowersion rate. Conversion to sinus rhythm was 
achieved in I I (55%) of the 20 patients with atrial fibrillation 
treated with propafenone (prop&tcne group) and in I8 
(9Ma) of the 20 with atriai tibriliation in the group treated 
wirb Aecainide (Recainide group) (p < 0.02). Atrial flurter 
was ionwteil to sinus rhythm in two (40%) of five in the 
propal&x,e group and one (20%) of five in the flecainide 
group Ip = NS). All ihree patients with atrial flutter con- 
vened lo sinus rhythm after a brief period of altial fibrilla- 
!iOR. 
Duration dthearrh:#m,ia. If ariaI fihrillat~on had been 
present ~24 h. the conversio. rate was 57% (8 of I4 patients) 
m the crop&tone group and 93% (I3 of I4 patients) in the 
flecainide goup (p c F.05). If a:;ial fibrillation lasted >24 h, 
50% (three of six patients) in the propofcnone group had 
conversion to sinus rhythm os did 83% (five of six patients) 
in the flecainide group (p = NV. The mean duration of atdal 
fibrillation (if nresent ~-24 h) was 7.7 k I I .1 davs (ranae 2 to 
30) in the pr&fcnone group and 4.2 t 2.4 d&s (r&c 2 to 
8) in the flecainide ~rouo C = NS). Atria1 flutter had been 
present 424 h in 3if the i0 patients. Conversion to sinus 
rhythm occurred in both pr+tieuts with recent onset atrial 
flutter who were treated wirh propaf..none. 
Conversion time. The time required for conversion to 
sinus rhythm in the propafcnone group WE 16 * 10 min 
(range 4 to 40). In the flecainioe group it was I8 * 13 min 
(range 3 to 47) (p = NS). 
Ekctroeardiographic mrasuvments. In the patients 
treated with propaf..none whose arrhythmia was not con- 
verted, slowing ofmean ventricular rate from 138 t 23 to 101 
-t 21 beatslmin (p < 0.001) after I h of the infusion was 
noted. The patients treated with flecrdnide whose arrhythmia 
was not converted showed a decrease in venrricular rate 
from I33 i 27 to II6 f 36 beatslmin (p < 0.05). The 
prop&none group showed no significant increase (mean 
3%) of the QRS interval from 83 + I I lo 86 ? I2 ms; the QT 
interval increased from 310 t 33 to 344 * 43 ms (p < 0.001) 
and the QTc interval dccrcascd from 473 2 46 to 416 2 M) ms 
(p < O.GiW. in the tlecainide group, the QRS interval 
signidcantly increased (mean 16%) from 83 + IS to 99 + 
20 ms (p < O.oOl), the QT interval increased from 314 ? 45 
to 370 ? 52 ms (p < OMJI) and the QTc interval decreased 
from 465 + 57 to 427 t 55 ms (p < 0.003). In both treatment 
groups with atrial flutter, there was a significant increase in 
atrial flutter cycle length from 216 2 22 to 272 f 59 ms in the 
propafenone group and from ZM) i 28 to 244 _c 46 ms in the 
flecainide group (p i 0.05 for both). 
Cardii measuremenk. The mean cardiothorasic index 
on a chest X-ray film was 0.46 + 0.06 in patients with 
successful conversion to sinus rhythm wsus 0.47 + 0.06 in 
the group without conversion (p = NS). In patients with 
atrial flutter, the mean cardiothoracic index was 0.50 C 0.01 
in the group with conversion and 0.41 + 0.05 in the group 
without conversion (p = NS). In patients with atrial fibtilla- 
tion, the mean anteroposterior left atrial size on two- 
dim&oral echocardiography was 38 + 6 mm (range 25 to 
48) in the group with conversion and 38 z 9 mm (range 23 to 
55) in the group without conversion (p = NS). Patients with 
atrial flutter whose arrhythmia converted had a mean left 
atrial size of 39 + 3 mm (range 37 to 42) compared with 38 + 
I I (range 27 to 55) in the group without conversion (p = NS). 
Revioos treatment with clam IA agenk. Eight of 16 
Patients with recurrent episodes ofatrial fibrillation or flutter 
had been treated previously with a class IA antiarrhythmic 
drug. Pharmacologic cardioversion to sinus rhythm was 
achieved in three of these patients. In three of be patients 
whose arrhythmia had not been converted during treatment 
Tabk 2. Adverse Effects During or After Iniravenous 
Ropafenone Hydrochloride or Recainide Acetate 
Fmpafrnonr FlWaln,de 
rn = 211 I” = *I) 
with a class IA ugenl the arrhythmia convened to sinus 
rhythm after intravenous administration of either pro- 
pafcnone or flecainide. 
Cooamitaul use of @oxin. Seven patients were rccciv- 
ing digoxin on entry irdo the study. Conversion to sinus 
rhythm was achieved in 5 (71%) of the 7 patients who 
received digoxin and in 27 (63%) of 43 without the concorn- 
itant use of digoxin (p = NS). 
Adverse elkets. Transient mild adverse effects were 
noted in IO patients (42%) in the Recainide group and in only 
2 vatients (8%) in the orooafenone PTOUD ID c 0.01) ITable 
2); Two patients in the flkainide g&p’hah more than one 
drug-related side effect. None of the patients required dis- 
continuation of the intravenous administration and no addi- 
tional treatment was required. 
PAWN kvds. Rap&none and flecainide plasma sam- 
ples were collected in all patients. At the time of conversion 
to sinus rhythm the meti plasma level of pmpafenone was 
1.26 + 0.71 mglliter, at 20minit wasO.90 + O.Mmgiliter and 
at 60 win OS6 t 0.24 mpniter. The mean plasma level of 
fkcrdnide at the time ofconversion to sinus rhythm was 0.53 
* 0.43 mfliter. at 20 min it was 0.37 * 0.23 mallitcr and at 
60 min O.jO + 0.08 mgiliter. There was a signi&nt ditTer- 
once in plasmalevels at 2Oand03miu when the @ientswith 
arrhythmiaconversion were compared with patients without 
conversion in the propafenone group (Table 3). In the 
tlecainide group plasma levels in the patients with arrhyth- 
ruia conversion were also higher, although this difference did 
not reach statistical signiticance. 
lang&‘m follow-up. Forty-nine patients remained in 
sinus rhythm and I patient had persisting &al fibrillation 
during a mean follow-up period of I I .4 + 5.2 months. After 
conversion to sinus rhythm most patients were treated orally 
with prop&tone, tlecainide. quinidine, sotalol or digoxin 
but six patients did not receive soy drug therapy. Sixteen of 
the medically treated patients experienced at last one 
symptomatic episode of suplaventriculru tachyarrhylhmia 
during the follow-up period and one patient had daily epi- 
sodes of alrial fibrillation despite various forms of therapy. 
Discussion 
Paroxysmal atria1 tibrillation is an extremely common 
tachyarrhylhmia in humans, whereas paroxysmal atrial 
flutter is less common (26.27). These rhvthm disturbances 
are frequently associated with very d&bins palpitntion 
and an increased risk for emholic cerebrovascular cvems or 
they may even result in more insidious symptoms r&ad to 
the loss of contribution of atrial systole to ventricular filling 
and subsequent cardiac output (28.29). Therefore. the rapid 
restoration of sinus rhythm in patients with paroxysmal 
atrial fibrillation or flutter is usually warranted. 
Acute therapy of paroxysmal atria1 fibriMioo or flolter. 
Control of ventricular response during atria.1 fibrillation or 
flutter can uwdly be achieved by various drugs and sinus 
rhythm can be restored by direct current countershock in 
most patients. Chemical cardioversion. especially if the drug 
is given orally, is seldom achieved rapidly and adverse 
effects ate frequently observed (20). During and shortly after 
intravenous drug administration overali conversion SUCECSS 
rates vary from 6% for verapamil to 58% for pmcainamide 
and S3% for Recainide (17,24.30). However. the “ideal” 
cardiovascular drug for restoration of sinus rhythm should 
be simple to administer, highly effective with a rapid onset of 
action and devoid of significant cardiac or noncardiac 1&c- 
ity. 
Comparkm with previous studies. In a previous report 
(24) we suggested that patients with recent onset atrial 
fibrillation and uncompromised left ventriwlar fuoction can 
be managed with intravenous Recainide rather rhan hosphal- 
ization for therapy with quinidine or electrical cardioversion. 
However, transient adverse effects during and shonly after 
Recainide infusion were still nored in 26% of the patients. 
F’mpafenane may be more suitable for the treatment of 
paroxysmal atrial fibrillation or flurter. Its electrophysiologic 
effects are similar to those nf Recamlde but only minor 
but not after acute intravenous adminis!mtion. is Qmbably 
rwonuhle for these adverse effects. 
Maior findings of the Q~SSX~ study. We repo~l here a 
ronrrollcd randomized study where the efficacy and rz.f<ty of 
intravenous Qropafenonc WAY compared with intravenous 
Recamde for acute conversion of parorywml anal fibrilla- 
tion or R~:iler to sinus rhythm with a delined end-Q&! for 
therapeutx wcces~ within I h after drug administraiion. 
thereby Ikwgcly eliminating the bias of spontaneous conver- 
sion. 
In rit:r .srwi,vflcrninidr hod an osumll cmwnm~ rmc of 
40% in pariom widt nrrinljhrillaiion: however. the cower- 
sion raw ~a* only 20% in Qatisnrc with atrial flutter. These 
recults are in agreement with Qrcwous Fludies (16.19.24). 
Qmpnfcnone showed a significant lower overall con~enion 
rate of 55% m patients wtth atrial fibrillation as compared 
with the Recainfde group. However. in Qropafenone-tr&ted 
parteotc with atria; Autler. WE found a converGon rate of 
4o%, although the number of observations was small. Com- 
pwable recults were obtained by Bianconi et al. (12) who 
reported an overnll conversion rate of 62% in patients with 
atrinl fibrillation and a 33% conversion rate in patients with 
atrril flutter. Connolly et al. (IO) found a conversion nte of 
43% in patients with srrial tibrilianon afier cardiac rurgay. 
In our rludy conversion to sinus rhythm was achwed very 
rapidly in both treatment groups. Both propafenonc and 
flecainide caused a significant decrease in the ventricular 
response it 60 min in the patients without arhythmic 
CODYWSlO”. 
If atria! fibrillation lasted 824 h tf was converted to sinus 
rhythm m almost all patients (93%) !r%?!?d with intravenous 
fiecaimdc. However, a significantly lower conversion rate of 
57% was noted with intravenous propafenone in this group 
of patients. No significant di&ence in conversion rate (five 
of six tlecainide-treated and three of six propafeoone-treated 
patientr) was seen Mveen the two treatment groups if atria1 
fibtillation lasted >24 h. although both grcups bad only a 
small number of patients. Bianconi et al. (12) reported a 
higher conversion rate of 11% in patients treated with 
propafenone when the arrhythmia lasted <48 h but only a 
26% converhioo rate in patien:s with a longer-lasting arrhyth- 
mia. In Qatients with long-standing atrial fibrillation (median 
duration I month, mean8.2 months). Vitae, al. (Il)repaled 
c conversion rate of only % in a p!acebacontrolled study 
with intravenous propafenone. 
Sigmficant QRS widening due to clawing of intraventric- 
ular conduction was noted only in the Recainide group. 
representing the conductian slowing cffecl of flecainide in 
rbe myocardium. Also, we nored reversible JeR bundle 
branch block in one w&n,. In conlras,. salients lreated 
with propafenone, &en those with high plasma levels. 
whose arrhythmia converted to sinus rhythms did ID! show 
significant QRS widening. QTc intervals showed a moderate 
decrease in both treatment groups, which is not suwising as 
the QTc interval largely repre&ts the refractory period. 
Neither Pmwfenone nor tlecainide substantially increases 
venhicular refractoriness. 
Different m venion rates of class IC drugs. The ekctro- 
physiologic mechanisms by which class IC drugs exert 
their beneficial effects for the conversion of atrial fibrillation 
or flutter to sinus rhythm remain speculative and have 
been discussed previously by our group (24) and by Amman 
et al. (31). The lower efficacy of Propafenone, as contrasted 
with fleca+dde. deserves further comment. There may be 
several reasons for the lower efficacy in our propafenone 
group: I) The plasma levels at 20 min in the Patients witb 
cunveraion to sinus rhythm were almost twice as high as 
the plasma levets of the Patients w&but arrhythmia oxwer- 
sion. This signiticant difference suggesrs that a high plasma 
level should be reached quickly to achieve an atrial tissue 
level sufficiently higb for early conversion to sinus rbytbm. 
This tendency was also found in the liecainide group. 
2) Apart from the lower efficacy in the propafenone-treated 
patients. there were also very few adverse effects in this 
group. 
Llmitatloar of tba study. The doses of both drugs used in 
this study were chosen on the basis of previously reported 
data. In most ofthese studies no intravenous dose >2 m&g 
body weight have been used for either propafenone or 
Recainide, in particular when the drug was given at an 
infusion rate of SIO min. However, the present study 
shows an evident discrepancy bc!ween the doses of both 
drugs tested. Flecainide produced the typical ECG changes 
of class IC antiarrhythmic agents and transient adverse 
effects at plasma levels in the “therapeutic” range. In 
contrast, propafenone caused no significant ECG changes 
and nre adverse effects with significantly lower plasma 
levels in the patients whose arrhythmia was not converted. 
It is obvious that both the pharmacokinetic and Pbamncc- 
dynamic behavior of prapafenone indicate- Ihat the 
optimal effective dose was not attained in this study. 
Either a higha: dosage or a faster rate of administration 
that leads to suflicientlv hieh tissue levels is ombablv 
necessary for greater &a&. Therefore. a d&-find& 
study with propafenone to determine the equipotcnt dosage 
or the optimal rate of administration, or both, s.?ems wa:- 
ranted. 
Cooelusions. Intravenous administration of the class 1C 
antiarrhythmic drugs propafenone and tlecaicide is very 
useful for immediate conversion of recent onset atrial fib& 
lation and may be preferable to oral loading with quinidine 01 
direct current countershock necessitating hospiralization. In 
airial flutler these drugs exert almost no effect. Al a dose of 
2 &kg in IO min. flecainide is more e&rive than pro- 
pafenone for conversion of paroxysmal atrial fibrillalion to 
sinus rhythm. However, one should use lhis drug cautiously 
and only during close KG monitoring, especially because of 
its transienl adverse effecls on cardiac conduction. In con- 
trast, propafcnone is almost free of adverse effects but has a 
lower efficacy than P.&aide. 

